PMID- 24261318
OWN - NLM
STAT- MEDLINE
DCOM- 20140930
LR  - 20151119
IS  - 1524-4741 (Electronic)
IS  - 1075-122X (Linking)
VI  - 20
IP  - 1
DP  - 2014 Jan-Feb
TI  - ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for 
      breast cancer treatment.
PG  - 37-45
LID - 10.1111/tbj.12223 [doi]
AB  - Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth 
      factor (HER2) concordance between immunohistochemistry (IHC) and fluorescence in 
      situ hybridization (FISH), and Oncotype DX, a commercially available RT-PCR-based 
      assay which recently began reporting biomarker results was assessed. ER 
      concordance was 98.9% (262/265), Pearson correlation coefficient (r) = 0.42, and 
      Spearman's rank correlation (rho) = 0.25. Positive percent agreement for ER was 
      98.9% (262/265). One patient with discordant ER results was not offered hormone 
      therapy based on the preferential use of Oncotype DX. PR was concordant in 91.3% 
      (242/265), r = 0.80, rho = 0.75, and Cohen's kappa (kappa) = 0.63. Positive percent 
      agreement for PR was 90.5% (218/241) and negative percent agreement was 100% 
      (24/24). HER2 concordance was 99.2% (245/247), r = 0.35, rho = 0.28, and kappa = 0.12. 
      Positive percent agreement for HER2 was 0% (0/2) and negative percent agreement 
      was 100% (245/245). Of the three FISH HER2-amplified cases, two were negative and 
      one was equivocal, and all FISH HER2-equivocal cases (n = 3) were negative by 
      Oncotype DX. Patients that were FISH HER2-amplified, Oncotype DX HER2-negative 
      did not receive trastuzumab. Although our results demonstrated high concordance 
      between IHC and Oncotype DX for ER and PR, our data showed poor positive percent 
      agreement for HER2. Compared to FISH, Oncotype DX does not identify HER2-positive 
      breast carcinomas. The preferential use of Oncotype DX biomarker results over IHC 
      and FISH is discouraged.
CI  - (c) 2013 Wiley Periodicals, Inc.
FAU - Park, MiHee M
AU  - Park MM
AD  - Department of Pathology, The Ohio State University Medical Center, Columbus, 
      Ohio.
FAU - Ebel, Joshua J
AU  - Ebel JJ
FAU - Zhao, Weiquiang
AU  - Zhao W
FAU - Zynger, Debra L
AU  - Zynger DL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20131122
PL  - United States
TA  - Breast J
JT  - The breast journal
JID - 9505539
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis/genetics
MH  - Breast Neoplasms/*genetics/*metabolism/therapy
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Receptor, ErbB-2/*genetics
MH  - Receptors, Estrogen/analysis/*metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Retrospective Studies
OTO - NOTNLM
OT  - RT-PCR
OT  - breast cancer
OT  - estrogen receptor
OT  - human epidermal growth factor
OT  - immunohistochemistry
OT  - oncotype DX
EDAT- 2013/11/23 06:00
MHDA- 2014/10/01 06:00
CRDT- 2013/11/23 06:00
PHST- 2013/11/23 06:00 [entrez]
PHST- 2013/11/23 06:00 [pubmed]
PHST- 2014/10/01 06:00 [medline]
AID - 10.1111/tbj.12223 [doi]
PST - ppublish
SO  - Breast J. 2014 Jan-Feb;20(1):37-45. doi: 10.1111/tbj.12223. Epub 2013 Nov 22.